Atrial Fibrillation
Thursday, August 7th, 2014
Heartrhythmjournal: July 25, 2014 Background Nonvalvular atrial fibrillation (AF) confers a five-fold increased risk of stroke. Whether catheter ablation (CA) subsequently decreases prothrombotic risk is unknown. Objective We sought to assess the long-term effects of CA for AF on prothrombotic risk. Methods Fifty-seven patients undergoing CA for AF were prospectively studied. Platelet activation (CD62P [platelet P-selectin] […]
Atrial Fibrillation
Thursday, August 7th, 2014
STROKEAHA: June 26, 2014 The overall prevalence of atrial fibrillation (AF) is 1% of the US population. However, diagnosis of AF is increasingly common with age, and prevalence rises to ≈10% in Americans aged >80 years. As the population ages, the estimated prevalence of AF may nearly triple from 2.3 million to 5.6 million US adults […]
Atrial Fibrillation
Thursday, August 7th, 2014
STROKEAHA: June 26, 2014 After complete diagnostic workup, a quarter of ischemic strokes are regarded as undetermined pathogenesis at discharge with a substantial rate of mortality in some cases.1 Paroxysmal atrial fibrillation (PAF) is the most frequent occult cause resulting in significant morbidity and costs when is under diagnosed.2 Recent studies have shown that extending the cardiac monitoring […]
Clinical Trials
Thursday, August 7th, 2014
Wiley: 31 JUL 2014 Background Sonothrombolysis is safe and may increase the likelihood of early recanalization in acute ischemic stroke patients. Aims In preparation of a phase III clinical trial, we contrast the likelihood of achieving a sustained recanalization and functional independence in a post hoc subgroup analysis of patients randomized to transcranial Doppler monitoring plus […]
Clinical Trials
Thursday, August 7th, 2014
Heartrhythmjournal: July 25, 2014 Abstract Background Atrial fibrillation (AF) recurrence after pulmonary vein isolation (PVI) is associated with PV to left atrium re-conduction. Effective lesion creation necessitates adequate contact force between the ablation catheter and myocardium. Objective We prospectively studied the utility of contact force guided ablation on immediate and long-term outcomes. Read More
Clinical Trials
Thursday, August 7th, 2014
STROKEAHA: June 24, 2014 Background and Purpose—Thrombosis of cerebral veins and sinus (cerebral venous thrombosis) is a rare stroke pathogenesis. Pharmaceutical treatment is restricted to heparin and oral anticoagulation with vitamin K antagonists (VKAs). Methods—Between January 2012 and December 2013, we recorded data from our patients with cerebral venous thrombosis. The modified Rankin scale was used […]
Clinical Trials
Thursday, August 7th, 2014
STROKEAHA: June 19, 2014 Background and Purpose—The once-daily oral factor Xa inhibitor, edoxaban, is as effective as warfarin in preventing stroke and systemic embolism while decreasing bleeding in a phase III trial of patients with atrial fibrillation at moderate–high stroke risk. Limited data regarding cerebrovascular events with edoxaban were reported previously. Methods—We analyzed the subtypes of […]
Clinical Trials
Thursday, August 7th, 2014
STROKEAHA: une 12, 2014 Background and Purpose—Right hemisphere stroke patients frequently experience spatial neglect, a severe lack of awareness for contralesional hemispace. Although neglect counts among the strongest predictors for poor functional outcome after stroke, there is no established therapy, particularly not for the acute stage. Methods—In a randomized controlled trial, we compared the combined treatment […]
Therapies
Thursday, August 7th, 2014
JAMA: July 28, 2014 Importance Intravenous thrombolysis remains the mainstay treatment for acute ischemic stroke. One of the most feared complications of the treatment is thrombolysis-related symptomatic intracerebral hemorrhage (sICH), which occurs in nearly 6% of patients and carries close to 50% mortality. The treatment options for sICH are based on small case series and expert opinion, and […]
Therapies
Thursday, August 7th, 2014
Wiley: 25 JUL 2014 Abstract Purpose To critically appraise the evidence on dabigatran etexilate, Pradaxa, as an alternative to warfarin for stroke prevention among patients with nonvalvular atrial fibrillation. This information can assist nurse practitioners in making informed treatment decisions. Data sources A review of the literature was conducted using CINAHL and PubMed databases. Reports […]
